Research Areas
- Nanomedicine – targeted nanoparticles, safety
- Disease Models – cancer, cardiovascular
- Neuroscience – brain function, disorders, injury, stroke, narcotics
- Pharmacology – drug development, metabolism, CNS interactions
- Image Analysis – AI-based detection & patterns
Scientific Achievements
Advancing research on diseases affecting disadvantaged populations through cutting-edge imaging and training. Key Functions:
- Provide advanced instrumentation, expertise, and services for preclinical imaging (nanomedicine, cancer, cardiovascular & neurological models).
- Maintain state-of-the-art MRI, PET, SPECT, CT & optical imaging machines.
- Train users via hands-on sessions & workshops.
- Promote collaborations within Howard and with HBCU RCMI programs & nearby institutions (Children’s National, Georgetown U, GWU, Catholic U, USDA).
Funding
RCMI Funding: NIH/NCRR/RCMI 2G12RR 00304816 00304816,NIH/NIMHD G12MD007597, 2U54MD007597
Equipment Funding/RCMI Support: NIH/NINDS 1S10NS140383; USAMRMC W911NF W911NF-17 -1-0515
Other Funding with RCMI Support: NIH/NICHD P50HD105328, U54HD090257; NIH/NINDS R01NS112294 , NIH/NHLBI R01HL060922, R01HL104173, R01HL128546; NSF 220489, 2200585
Training Grants Support: USAMRMC 17-00-1-0291, 17-01-1-0267, W81XWH-05-1-0291, W81XWH-10-1-0767
Equipment Funding/RCMI Support: NIH/NINDS 1S10NS140383; USAMRMC W911NF W911NF-17 -1-0515
Other Funding with RCMI Support: NIH/NICHD P50HD105328, U54HD090257; NIH/NINDS R01NS112294 , NIH/NHLBI R01HL060922, R01HL104173, R01HL128546; NSF 220489, 2200585
Training Grants Support: USAMRMC 17-00-1-0291, 17-01-1-0267, W81XWH-05-1-0291, W81XWH-10-1-0767
Scientific Advance
Innovations in Molecular Imaging and Nanotechnology Applications
Publication: www.ncbi.nlm.nih.gov/myncbi/paul.wang.1/bibliography/public/
Publication: www.ncbi.nlm.nih.gov/myncbi/paul.wang.1/bibliography/public/
Dr. Wang’s research has advanced the field of molecular imaging and nanomedicine through the development of novel MRI MRI-based probes, engineered nanomaterials, and translational applications. He has:
- Pioneered multimodal imaging probes by engineering transferrin transferrin-targeted liposomal nanocarriers that integrate magnetic resonance and near near-infrared optical imaging, enabling precise detection of tumor heterogeneity and transferrin receptor receptor–overexpressing cancers.
- Advanced cancer diagnostics and therapeutics by applying metallofullerene nanoparticles to overcome drug resistance in prostate cancer, restoring endocytosis and enhancing cisplatin efficacy.
- Contributed to nanomedicine’s foundations through reviews and international collaborations that addressed the biopharmaceutics, safety, and translational potential of engineered nanomaterials in cancer and other diseases.
- Extended MRI applications to neuroscience and clinical models, demonstrating microstructural white matter injury after pediatric cardiac surgery and linking fractional anisotropy changes to cellular pathology.
Together, these contributions bridge basic nanomaterial engineering, molecular imaging innovation, and translational medicine, laying the groundwork for more sensitive disease detection, improved therapeutic strategies, and global scientific collaboration in nanomedicine.
NIH/NIMHD 2G12RR003048, G12 MD007597; NIH/NHLBI/R01HL060922, R01HL104173, R01HL128546; NIH/NICHD/U54HD090257; USAMRMC W81XWH-10-1-0767
